Article
Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States
29 May 2020
Abstract excerpt
PURPOSE: Multiple myeloma (MM) treatment has changed tremendously, with significant improvement in patient out-comes. One group with a suboptimal benefit is patients with high-risk cytogenetics, as tested by conventional karyotyping or fluorescence in situ hybridization (FISH). Methodology for these tests has been published, but not necessarily standardized. METHODS: We address variability in the testing and...